Neboglamine information

Neboglamine
Clinical data
Other names	Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine
ATC code	None;
Identifiers
	IUPAC name (4S)-4-Amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid;
CAS Number	163000-63-3;
PubChem CID	3074827;
ChemSpider	2333649;
UNII	12EA34U5B8;
CompTox Dashboard (EPA)	DTXSID2045787 ;
ECHA InfoCard	100.162.081
Chemical and physical data
Formula	C13H24N2O3
Molar mass	256.346 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCC(CC1)NC(=O)C(CCC(=O)O)N)C;
	InChI InChI=1S/C13H24N2O3/c1-13(2)7-5-9(6-8-13)15-12(18)10(14)3-4-11(16)17/h9-10H,3-8,14H2,1-2H3,(H,15,18)(H,16,17)/t10-/m0/s1; Key:VCRGLZYPNNAVRP-JTQLQIEISA-N;

Neboglamine (INNTooltip International Nonproprietary Name) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence.^[1]^[2]^[3]^[4]^[5]^[6] It shows cognition- and memory-enhancing effects in animal models.^[7]^[8]^[9] As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.^[10]

^ Chiusaroli R, Garofalo P, Espinoza S, Neri E, Caselli G, Lanza M (May 2010). "Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat". Pharmacological Research. 61 (5): 430–6. doi:10.1016/j.phrs.2009.12.010. PMID 20045056.
^ Kantrowitz J, Javitt DC (March 2012). "Glutamatergic transmission in schizophrenia: from basic research to clinical practice". Current Opinion in Psychiatry. 25 (2): 96–102. doi:10.1097/YCO.0b013e32835035b2. PMC 5224527. PMID 22297716.
^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.
^ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (November 2012). "Novel NMDA receptor modulators: an update". Expert Opinion on Therapeutic Patents. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.
^ Zink M, Correll CU (May 2015). "Glutamatergic agents for schizophrenia: current evidence and perspectives". Expert Review of Clinical Pharmacology. 8 (3): 335–52. doi:10.1586/17512433.2015.1040393. PMID 25916667. S2CID 39547774.
^ Köster LS, Carbon M, Correll CU (December 2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–31. doi:10.1517/14728214.2014.958148. PMID 25234340. S2CID 42729570.
^ Garofalo P, Colombo S, Lanza M, Revel L, Makovec F (December 1996). "CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice". The Journal of Pharmacy and Pharmacology. 48 (12): 1290–7. doi:10.1111/j.2042-7158.1996.tb03938.x. PMID 9004193. S2CID 34902435.
^ Lanza M, Bonnafous C, Colombo S, Revel L, Makovec F (August 1997). "Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex". Neuropharmacology. 36 (8): 1057–64. doi:10.1016/S0028-3908(97)00092-0. PMID 9294970. S2CID 11958361.
^ Lanza M, Makovec F (1997). "Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator". CNS Drug Reviews. 3 (3): 245–259. doi:10.1111/j.1527-3458.1997.tb00326.x. ISSN 1080-563X.
^ "Neboglamine". AdisInsight. Retrieved 2015-06-10.

[ChiusaroliGarofalo2010-1] Chiusaroli R, Garofalo P, Espinoza S, Neri E, Caselli G, Lanza M (May 2010). "Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat". Pharmacological Research. 61 (5): 430–6. doi:10.1016/j.phrs.2009.12.010. PMID 20045056.

[KantrowitzJavitt2012-2] Kantrowitz J, Javitt DC (March 2012). "Glutamatergic transmission in schizophrenia: from basic research to clinical practice". Current Opinion in Psychiatry. 25 (2): 96–102. doi:10.1097/YCO.0b013e32835035b2. PMC 5224527. PMID 22297716.

[3] "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.

[SantangeloAcker2012-4] Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (November 2012). "Novel NMDA receptor modulators: an update". Expert Opinion on Therapeutic Patents. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.

[ZinkCorrell2015-5] Zink M, Correll CU (May 2015). "Glutamatergic agents for schizophrenia: current evidence and perspectives". Expert Review of Clinical Pharmacology. 8 (3): 335–52. doi:10.1586/17512433.2015.1040393. PMID 25916667. S2CID 39547774.

[KösterCarbon2014-6] Köster LS, Carbon M, Correll CU (December 2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–31. doi:10.1517/14728214.2014.958148. PMID 25234340. S2CID 42729570.

[GarofaloColombo1996-7] Garofalo P, Colombo S, Lanza M, Revel L, Makovec F (December 1996). "CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice". The Journal of Pharmacy and Pharmacology. 48 (12): 1290–7. doi:10.1111/j.2042-7158.1996.tb03938.x. PMID 9004193. S2CID 34902435.

[LanzaBonnafous1997-8] Lanza M, Bonnafous C, Colombo S, Revel L, Makovec F (August 1997). "Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex". Neuropharmacology. 36 (8): 1057–64. doi:10.1016/S0028-3908(97)00092-0. PMID 9294970. S2CID 11958361.

[LanzaMakovec1997-9] Lanza M, Makovec F (1997). "Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator". CNS Drug Reviews. 3 (3): 245–259. doi:10.1111/j.1527-3458.1997.tb00326.x. ISSN 1080-563X.

[AdisInsight-10] "Neboglamine". AdisInsight. Retrieved 2015-06-10.

Neboglamine information

and 29 Related for: Neboglamine information

Neboglamine

Ketamine

Magnesium

Nitrous oxide

Pentobarbital

Zinc

Diethyl ether

Phencyclidine

Barbiturate

Haloperidol

Hydrochlorothiazide

Saffron

Chloroform

Dextromethorphan

Phenobarbital

Glycine

Furosemide

Tramadol

Methadone

Nitric oxide

NMDA receptor

Xenon

Glutathione

Pethidine

Dehydroepiandrosterone

Sodium thiopental

Glutamic acid

Toluene

Topiramate